Harpoon Therapeutics raises $70M Series C for T-cell engager therapies
The company is currently running a Phase I study in prostate cancer and plans to advance additional therapies into Phase I trials and IND-enabling studies next year.
Chinese-American startup Terns Pharmaceuticals raises $80M for NASH, cancer drugs
The company joins a growing wave of firms developing drugs for the disease, which has no approved treatments. It expects to enter two drugs into the clinic next year.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.